Novel therapies in the treatment of ulcerative colitis.
Ulcerative colitis is a chronic inflammatory disease of unknown cause. Its course is one of relapse and remission and requires therapy for both the induction and maintenance of remission. The progress in the fields of genetics and immunology has afforded important advances in our understanding of the inflammatory process. Traditional therapy with non-specific anti-inflammatories for ulcerative colitis remains our gold standard as newer targeted therapies have failed to provide any improved efficacy. This review examines the most recent compounds in development for the treatment of ulcerative colitis, including data from early clinical trials and the potential clinical impact of future entities.
Kane
S V
SV
Department of Medicine, Division of Gastroenterology, University of Chicago, 5841 South Maryland Ave, MC 4076, Chicago IL 60637, USA. skane@medicine.bsd.uchicago.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000628:therapy*; D006801:Humans
D000911:Antibodies, Monoclonal